Holen Sie sich die Stockscreener-App
11.31
5.43%
-0.65
Handel nachbörslich:
11.38
0.07
+0.62%
Schlusskurs vom Vortag:
$11.96
Offen:
$11.94
24-Stunden-Volumen:
30,951
Relative Volume:
0.57
Marktkapitalisierung:
$45.74M
Einnahmen:
$147.75M
Nettoeinkommen (Verlust:
$-284.23M
KGV:
-3.8601
EPS:
-2.93
Netto-Cashflow:
$-317.54M
1W Leistung:
+1.62%
1M Leistung:
+63.20%
6M Leistung:
+25.53%
1J Leistung:
+13.21%
1-Tages-Spanne:
$11.31
$12.40
1-Wochen-Bereich:
$10.98
$12.60
52-Wochen-Spanne:
$4.50
$21.94
Fibrogen Inc Stock (FGEN) Company Profile
Firmenname
Fibrogen Inc
Sektor
Branche
Telefon
415-978-1200
Adresse
350 BAY STREET, SAN FRANCISCO, CA
Vergleichen Sie FGEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
11.31 | 49.25M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-06-26 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-06-26 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-06-26 | Herabstufung | Stifel | Buy → Hold |
| 2023-06-26 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-06-02 | Hochstufung | Stifel | Hold → Buy |
| 2023-01-31 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-01-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-09-22 | Herabstufung | Goldman | Neutral → Sell |
| 2021-08-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-07-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-07-16 | Herabstufung | Stifel | Buy → Hold |
| 2021-04-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-07 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-03-31 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-03-02 | Herabstufung | Jefferies | Buy → Hold |
| 2021-02-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-10-26 | Eingeleitet | Raymond James | Underperform |
| 2020-07-10 | Fortgesetzt | Stifel | Buy |
| 2020-05-01 | Eingeleitet | Cowen | Market Perform |
| 2020-04-27 | Eingeleitet | BofA/Merrill | Neutral |
| 2019-05-29 | Fortgesetzt | Goldman | Neutral |
| 2019-05-10 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Neutral |
| 2019-02-11 | Fortgesetzt | Stifel | Buy |
| 2018-12-19 | Hochstufung | Citigroup | Neutral → Buy |
| 2017-08-08 | Bestätigt | Leerink Partners | Outperform |
| 2017-08-08 | Bestätigt | Stifel | Buy |
| 2017-07-21 | Herabstufung | Goldman | Buy → Neutral |
| 2017-07-11 | Eingeleitet | Jefferies | Buy |
| 2016-02-11 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2016-01-21 | Eingeleitet | Credit Suisse | Neutral |
| 2015-12-04 | Eingeleitet | Citigroup | Buy |
| 2015-09-23 | Eingeleitet | Lake Street | Hold |
| 2015-07-29 | Eingeleitet | Citigroup | Buy |
| 2015-07-20 | Hochstufung | Goldman | Neutral → Buy |
| 2014-12-09 | Eingeleitet | Stifel | Buy |
Alle ansehen
Fibrogen Inc Aktie (FGEN) Neueste Nachrichten
FibroGen Sells Subsidiary to AstraZeneca for $220M - MSN
Using fundamentals and technicals on FibroGen Inc.2025 Technical Patterns & Stepwise Entry/Exit Trade Alerts - Newser
What are analysts’ price targets for FibroGen Inc.Inflation Watch & Stepwise Trade Execution Plans - khodrobank.com
Will breakout in FibroGen Inc. lead to full recovery2025 Risk Factors & Intraday High Probability Alerts - Newser
Is FibroGen Inc. stock a value trapDip Buying & Low Risk Entry Point Tips - khodrobank.com
Using data filters to optimize entry into FibroGen Inc.Earnings Trend Report & Trade Opportunity Analysis Reports - Newser
Regression analysis insights on FibroGen Inc. performance2025 Trade Ideas & Reliable Intraday Trade Alerts - Newser
Is FibroGen Inc. stock entering bullish territory2025 Volatility Report & Safe Capital Growth Plans - Newser
Price momentum metrics for FibroGen Inc. explainedQuarterly Performance Summary & Reliable Price Breakout Signals - Newser
How to build a dashboard for FibroGen Inc. stockWeekly Market Report & Low Volatility Stock Recommendations - Newser
Can machine learning forecast FibroGen Inc. recovery2025 Analyst Calls & Consistent Growth Equity Picks - Newser
Is FibroGen Inc. stock poised for growthPortfolio Gains Summary & Community Consensus Picks - Newser
Volume spikes in FibroGen Inc. stock – what they mean2025 Dividend Review & Fast Momentum Stock Entry Tips - Newser
FibroGen stock maintains Buy rating at H.C. Wainwright after China sale - Investing.com
How hedge fund analytics apply to FibroGen Inc. stockJobs Report & Community Verified Watchlist Alerts - Newser
Using R and stats models for FibroGen Inc. forecastingWeekly Risk Report & Advanced Swing Trade Entry Plans - Newser
How sentiment analysis helps forecast FibroGen Inc.July 2025 Analyst Calls & Daily Oversold Stock Bounce Ideas - Newser
FibroGen Inc. stock outlook for YEARJuly 2025 Levels & Weekly High Conviction Ideas - Newser
Is FibroGen Inc. stock forming a triangle patternJuly 2025 Setups & Verified Trade Idea Suggestions - khodrobank.com
What technical models suggest about FibroGen Inc.’s comebackEntry Point & Smart Investment Allocation Insights - Newser
Custom strategy builders for tracking FibroGen Inc.Portfolio Risk Summary & AI Powered Market Trend Analysis - Newser
How to use a screener to detect FibroGen Inc. breakoutsWeekly Profit Analysis & Breakout Confirmation Alerts - Newser
How does FibroGen Inc. score in quality rankingsInsider Selling & Free High Return Stock Watch Alerts - khodrobank.com
Smart tools for monitoring FibroGen Inc.’s price actionJuly 2025 Spike Watch & Free Reliable Trade Execution Plans - Newser
FibroGen Completes Sale of Chinese Subsidiary to AstraZeneca - MarketScreener
FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million - GlobeNewswire
$220M Deal: FibroGen Divests China Operations to AstraZeneca, Extends Cash Runway to 2028 - Stock Titan
Applying big data sentiment scoring on FibroGen Inc.2025 Market Sentiment & Free Safe Capital Growth Stock Tips - Newser
Aug Drivers: What’s the analyst consensus on FibroGen Inc.2025 Key Highlights & Consistent Income Trade Ideas - khodrobank.com
Breakouts Watch: Can FibroGen Inc. deliver consistent dividends2025 Macro Impact & Weekly Market Pulse Updates - khodrobank.com
Is a relief rally coming for FibroGen Inc. holdersTrade Exit Summary & Proven Capital Preservation Tips - Newser
Can FibroGen Inc. reach all time highs this yearJuly 2025 Action & Growth Oriented Trade Recommendations - khodrobank.com
FibroGen Inc. stock daily chart insightsMarket Movers & AI Powered Trade Plan Recommendations - Newser
What indicators show strength in FibroGen Inc.Earnings Overview Report & Long-Term Growth Portfolio Plans - Newser
Is FibroGen Inc. a good ESG investment2025 Breakouts & Breakdowns & Weekly Return Optimization Alerts - khodrobank.com
Traders Watching For Reversal Pattern in FibroGen Inc. getLinesFromResByArray error: size == 0 - thegnnews.com
Using Python tools to backtest FibroGen Inc. strategiesWeekly Trade Analysis & Consistent Growth Stock Picks - Newser
Finanzdaten der Fibrogen Inc-Aktie (FGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Fibrogen Inc-Aktie (FGEN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Wettig Thane | CEO |
Mar 24 '25 |
Buy |
0.35 |
145,000 |
50,663 |
543,329 |
| Schoeneck James A | Director |
Mar 20 '25 |
Buy |
0.35 |
250,000 |
88,000 |
323,722 |
| Schoeneck James A | Director |
Mar 21 '25 |
Buy |
0.34 |
50,000 |
17,040 |
373,722 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):